Compare · LLY vs OKUR
LLY vs OKUR
Side-by-side comparison of Eli Lilly and Company (LLY) and OnKure Therapeutics Inc. (OKUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and OKUR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 6544.9x OKUR ($169.7M).
- Over the past year, LLY is up 52.7% and OKUR is up 82.2% - OKUR leads by 29.5 points.
- LLY has been more active in the news (11 items in the past 4 weeks vs 3 for OKUR).
- LLY has more recent analyst coverage (25 ratings vs 3 for OKUR).
- Company
- Eli Lilly and Company
- OnKure Therapeutics Inc.
- Price
- $1178.57+0.73%
- $4.19+2.07%
- Market cap
- $1.11T
- $169.7M
- 1M return
- +5.00%
- -1.64%
- 1Y return
- +52.71%
- +82.17%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 11
- 3
- Recent ratings
- 25
- 3
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
Latest OKUR
- OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
- President and CEO Saccomano Nicholas A sold $378 worth of shares (86 units at $4.40), decreasing direct ownership by 0.76% to 11,247 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Leverone Jason A. sold $1,332 worth of shares (303 units at $4.40), decreasing direct ownership by 2% to 18,802 units (SEC Form 4) (for tax liability)
- SEC Form 4 filed by Director Mathers Edward T
- SEC Form 4 filed by Director Ratcliffe Liam
- SEC Form 4 filed by Director Phillips Andrew John
- SEC Form 4 filed by Director Jansen Valerie Malyvanh
- SEC Form 4 filed by Director Grey Michael G
- SEC Form 4 filed by Director Carruthers R Michael
- SEC Form S-8 filed by OnKure Therapeutics Inc.